XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Revenue related to Sanofi agreement:
Revenues	$ 6,835	$ 29,378	$ 164,792	$ 57,609
Novartis Institutes for BioMedical Research, Inc.
Revenue related to Sanofi agreement:
Revenues	2,426	10,928	12,181	19,823
Novartis Institutes for BioMedical Research, Inc. | License and Service
Revenue related to Sanofi agreement:
Revenues	1,872	8,622	9,568	15,640
Novartis Institutes for BioMedical Research, Inc. | Research services
Revenue related to Sanofi agreement:
Revenues	554	2,306	2,613	4,183
Biogen MA, Inc.
Revenue related to Sanofi agreement:
Revenues	2,204	10,052	134,506	21,245
Biogen MA, Inc. | License and Service
Revenue related to Sanofi agreement:
Revenues			132,165	14,612
Biogen MA, Inc. | License
Revenue related to Sanofi agreement:
Revenues	1,535	7,306
Biogen MA, Inc. | Research services
Revenue related to Sanofi agreement:
Revenues	669	2,746	2,341	6,633
Kite Pharma, Inc.
Revenue related to Sanofi agreement:
Revenues	1,231	6,334	13,539	12,642
Kite Pharma, Inc. | License and Service
Revenue related to Sanofi agreement:
Revenues			12,550	12,386
Kite Pharma, Inc. | License
Revenue related to Sanofi agreement:
Revenues	1,110	6,227
Kite Pharma, Inc. | Research services
Revenue related to Sanofi agreement:
Revenues	$ 121	$ 107	$ 989	$ 256

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenuesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: